The product has not yet been released on the market.
Description
Linagliptin/Metformin Tchaikapharma contains the active substances linagliptin and metformin and belongs to the group of medicines used for the treatment of type 2 diabetes mellitus. Linagliptin increases insulin secretion and reduces blood glucose levels, while metformin decreases glucose production in the body and improves insulin sensitivity. Their combined action helps to achieve effective blood glucose control.
Indications
Linagliptin/Metformin Tchaikapharma is indicated in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:
- in patients who have not achieved adequate glycemic control with the maximum tolerated dose of metformin administered as monotherapy;
- in combination with other medicinal products for the treatment of diabetes, including insulin, in patients who have not achieved adequate glycemic control with metformin and these medicinal products;
- in patients already treated with a combination of linagliptin and metformin administered as separate tablets.
Subject to medical prescription.
Concentration and pharmaceutical form: 2,5 mg /850 mg; 2,5 mg /1000 mg film-coated tablets